Atlas Trials

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women

Clinical trial NCT03293108 · UNKNOWN

Trial details

NCT number
NCT03293108
Sponsor
AryoGen Pharmed Co.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Osteoporosis
Start date
2017-04-29
Primary completion
2020-09-30
Enrollment
190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.